Chronic exposures to inorganic arsenic (iAs) have been linked to increased incidences of various cancers, including cancer of the urinary bladder. Mechanisms by which iAs promotes cancer may include stimulation of activator protein-1 (AP-1) DNA binding through increased expression and/or phosphorylation of the AP-1 constituents. However, the role of methylated metabolites of iAs in AP-1 activation has not been thoroughly examined. In this study, we show that short-time exposures to 0.1-5 µM arsenite (iAs 
E pidemiological evidence demonstrates that inorganic arsenic (iAs) is a potent human carcinogen (1) . Chronic exposures to iAs are associated with increased prevalence of skin cancer and cancers of internal organs, including lung, liver, kidney, and bladder (2, 3) . In populations worldwide, drinking water contaminated with arsenite (iAs III ) or arsenate (iAs V ) is the major source of exposure to iAs (4) . The mechanisms by which iAs induces cancer have not been thoroughly characterized. Elucidation of these mechanisms in laboratory studies has been hindered by the lack of an adequate animal model. Therefore, many ex vivo mechanistic studies have been carried out with cultured human cells, including cells derived from tissues that are targets for carcinogenic effects of iAs. These studies suggest that iAs is not a classic genotoxin or mutagen but rather may act as a cocarcinogen in combination with a genotoxic agent (5) . In addition, iAs modifies signal transduction pathways that are involved in the regulation of cell growth and proliferation (6) . It has been shown that iAs III modulates the expression and/or DNA binding activities of several transcription factors associated with cell proliferation and death, including nuclear factor-κB (NF-κB) (7, 8) , tumor suppressor 53 (p53) (9) , a GC-box specific transcription factor Sp1 (10), a Y-box specific transcription factor-1 (YB-1) (10) , and activator protein-1 (AP-1) (11) (12) (13) . Examination of mechanisms involved in the AP-1 activation indicates that iAs III stimulates the mitogen-activated protein kinase (MAPK) cascade, thus inducing expression of c-jun and c-fos protooncogenes and enhancing DNA binding activity of AP-1 (12, (14) (15) (16) (17) . The modulation of AP-1-dependent gene transcription by iAs III may contribute to the induction of proliferation in cells exposed to this arsenical (13, 17) .
Most studies of the molecular mechanisms involved in arsenic carcinogenesis have focused on iAs species, particularly iAs III , and little attention has been given to methylated arsenicals, which are metabolites of iAs. In humans and many other mammalian species, iAs is metabolized to methylarsenic species (MAs) and dimethylarsenic species (DMAs) (18) (19) (20) . The metabolic pathway for iAs includes both reduction and oxidative methylation steps, during which arsenic cycles between +5 and +3 oxidation states (21, 22 , directly damage DNA in an in vitro system or in intact cells (29) . Thus, production of these methylated species that contain As III should properly be regarded as a process for activation of iAs as a toxin and a carcinogen. Because both MAs III and DMA III have been detected in urine of individuals chronically exposed to iAs from drinking water (30) (31) (32) (33) (34) , it is likely that these highly toxic and potentially genotoxic species are significant and persistent products of iAs metabolism in humans.
To characterize the role of arsenic metabolites in the activation of AP-1-dependent gene transcription, we have examined composition and DNA binding activity of AP-1 in UROtsa, a human urinary bladder epithelial cell line, exposed to inorganic or methylated arsenicals that contain trivalent or pentavalent arsenic. We found that short-time exposures to micromolar concentrations of inorganic or methylated trivalent arsenicals significantly increased the nuclear level of phospho-c-Jun (p-c-Jun) and the DNA binding activity of AP-1. Notably, methylated trivalent arsenicals are considerably more potent inducers of c-Jun phosphorylation and activators of AP-1 DNA binding than is iAs III . Analysis of MAPK activation patterns suggests that extracellular signal-regulated kinases (ERKs), but not c-Jun N-terminal kinase (JNK) or p38 kinases, are responsible for c-Jun phosphorylation and AP-1 activation in exposed cells. Hence ,  MAs  III and DMAs   III , methylated trivalent metabolites produced during iAs metabolism, likely contribute to the activation of AP-1 and to the induction of the AP-1-regulated gene transcription. 
MATERIALS AND METHODS

Arsenic
Cell cultures and treatment
UROtsa, an SV40-immortalized cell line derived from normal human urothelium (37, 38) , was obtained from Dr. Nyseo Unimye (West Virginia University, Morgantown, WV). The UROtsa cells were maintained in Eagle's minimum essential medium (MEM; GIBCO BRL, Grand Island, NY) containing 2 mM glutamine (Sigma), 10% FBS (GIBCO), 1 mM sodium pyruvate (GIBCO), 0.1 mM nonessential amino acids (GIBCO), 1.5 µg/ml sodium bicarbonate (GIBCO), 50 U/ml penicillin (Sigma), and 50 µg/ml streptomycin (Sigma). For analyses of MAPKs, cells were serum starved (1% of FBS) for 16 h before exposure to arsenicals. Cells were cultured in 60- Radiolabeled metabolites were analyzed in both cells and media by thin-layer chromatography (36) .
Cell viability and proliferation assays
Effects of arsenicals on cell viability were examined by using the MTT (thiazolyl blue) assay (39) . This assay monitors conversion of MTT to insoluble purple formazan in a reaction catalyzed by mitochondrial dehydrogenases in viable cells. For the MTT assay, cell culture medium was removed, cells were washed with PBS, and the corresponding phenol red-free medium was added. MTT (Sigma) was added at a final concentration of 0.5 mg/ml, and cells were incubated at 37 o C for 3 h. After incubation, medium was removed and cells were washed with PBS. The insoluble formazan was then dissolved in dimethyl sulfoxide (Sigma). Absorbance of the dye was measured at 570 nm with background subtraction at 630 nm. The effects of arsenicals on cell proliferation were measured by quantitating the incorporation of 
Cytoplasmic and nuclear protein extracts
For harvesting, cell monolayers were washed twice with ice-cold PBS containing 1 mM dithiothreitol (DTT; Sigma) and the protease inhibitors 2.5 µg/ml aprotinin (Sigma), 1 µg/ml leupeptin (Sigma), 1 µg/ml pepstatin A (Sigma), and 1 mM phenylmethylsulfonyl fluoride (PMSF; Sigma). Cells were lysed on ice with 250 µl of cold cytoplasmic extraction buffer (40) containing protease inhibitors (as above) and transferred into test tubes. After a 10-min incubation on ice, 2.5 µl of 10% Nonidet P-40 (Sigma) was added to each tube, and samples were vortexed. Soluble cytoplasmic extracts were separated from cell lysates by centrifugation at 12,000g for 5 min at 4°C. Nuclear fractions were washed gently with the cytoplasmic extraction buffer (200 µl/sample) without Nonidet P-40 and centrifuged at 12,000g for 5 min (4°C). Each washed nuclear fraction was then treated with 75 µl of cold nuclear extraction buffer (40) containing protease inhibitors (as above). The nuclear extracts were maintained on ice for 1 h with occasional vortexing. Finally, nuclear protein extracts were clarified by centrifugation at 12,000g for 5 min (4°C) and stored at −80°C until analyzed.
For MAPK analyses, cells were lysed for 30 min on ice in 20 mM HEPES (pH 7.4) buffer containing 50 mM β-glycerolphosphate (Sigma), 1% Triton X-100 (Sigma), 10% glycerol (GIBCO), 2 mM EGTA (Sigma), 1 mM DTT, 10 mM NaF (Sigma), 1 mM Na 3 VO 4 (Sigma), 0.5 µM okadaic acid (Sigma), 1 mM PMSF, and, each at 2 µM, aprotinin, pepstatin A, and leupeptin. Cell lysates were passed through a 22-gauge needle and vortexed for 1 min at 4°C. Cells debris was removed by centrifugation at 12,000g for 15 min at 4°C. The bicinchoninic acid microassay kit (Sigma) was used to determine protein concentrations in final extracts. Equal amounts of protein were used for immunoblot analysis.
Immunoblot analysis
Nuclear or cytoplasmic proteins (20 µg each) were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis on 10% or 12% gel slabs. Separated proteins were electroblotted on PVDF membranes and blocked for 1 h with 5% nonfat milk in PBS (Bio-Rad, Hercules, CA). The membranes were washed with PBS containing 0.1% Tween 20 and probed (1:5000) with rabbit polyclonal antibody specific to c-Jun p39 (sc-44; Santa Cruz Biotechnology, Santa Cruz, CA), c-Fos p62 (sc-52; Santa Cruz Biotechnology), and Fra-1 (sc-605X; Santa Cruz Biotechnology). Phosphorylated c-Jun (p-c-Jun) was detected by using mouse monoclonal antibody (sc-822; Santa Cruz Biotechnology). Enzymes of the MAPK family, JNKs 1 and 2 (JNK1,2), p38, and ERKs 1 and 2 (ERK1,2), were analyzed by using rabbit polyclonal antibodies from Cell Signaling Technology (NEB, Beverly, MA). Mouse monoclonal antibodies from this supplier were used to detect phosphorylated forms of these kinases (p-JNK1,2, p-p38, and p-ERK1,2). Antigen-antibody complexes were stained with horseradish peroxidaseconjugated goat anti-rabbit or anti-mouse antibodies (1:2000; Santa Cruz Biotechnology) and treated with an enhanced chemiluminescence reagent, Super Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL). Immunoblot images were digitized, and the optical densities of specific antigen-antibody complexes were quantified by using the Gene Gnome imaging system supported with the Gene Tools software package (both from Syngene, Frederick, MD).
Electrophoretic mobility shift assay (EMSA)
The 5'-ends of double-stranded oligonucleotides that contain an AP-1 consensus sequence (5'-TGAGTCAG-3', Promega, Madison, WI) were labeled with [γ-
32 P]ATP (Amersham Pharmacia Biotech, Piscataway, NJ), using 15 U of T4 polynucleotide kinase (New England Biolabs, Northampton, MA) at 37°C for 30 min. DNA-protein binding reactions were performed at room temperature for 10 min in reaction mixtures containing 6 µg of nuclear proteins, 2 µg of poly(dIdC) ⋅ poly(dI-dC) (Boehringer Ingelheim, Baltimore, MD), approximately 1 ng (2 × 10 6 cpm) of radiolabeled probe, and buffer (10 mM Tris-HCl, 50 mM NaCl, 2 mM EDTA, 5% glycerol, and 1 mM DTT, pH 7.9). For supershift analyses, antibodies specific for the AP-1 constituents were added to the reaction mixture (2 µg/assay). Antibodies from two manufacturers were used, including rabbit polyclonal antibodies against c-Jun, c-Fos, Fra-1, ATF-2, and mouse monoclonal antibodies against p-c-Jun and p-ATF-2 (all from Santa Cruz Biotechnology), and rabbit polyclonal antibodies against human c-Jun, JunB, JunD, c-Fos, and FosB supplied in the Nushift Kit (Geneka Biotechnology, Montreal, Canada). A nuclear protein extract from 3T3 SR (serum-responsive mouse embryo) cells (Nushift Kit, Geneka Biotechnology) served as a positive control for the supershift analysis. A neutralizing c-Fos peptide (Nushift Kit, Geneka Biotechnology) was used in the assay to confirm the specificity of antibodies against c-Fos. A 50-fold excess of unlabeled wild-type or mutant AP-1 probe was used to establish the binding specificity. The whole DNA-protein binding reaction mixtures were separated in 4% nondenaturing polyacrylamide gels in a high ionic strength running buffer (25 mM Tris, 190 mM glycine, 1 mM EDTA, pH 8.5). Gels were dried at 80°C for 1 h and analyzed by a phosphorimager (Molecular Dynamics, Sunnyvale, CA).
Promoter-reporter constructs, transient transfection, and promoter-reporter assay
Two promoter-reporter constructs were used in this study: pAP-1-luc (Stratagene, San Diego, CA) that is composed of a sevenfold tandem repeat of the AP-1 response element cloned upstream of a TATA box and firefly luciferase cDNA, and an SV-40 promoter-β-galactosidase construct, pSV-β-gal (Promega). The activity of constitutively expressed β-galactosidase was used to normalize for plate-to-plate variations in transfection efficiency, cell number, and viability. For transfection, cells were treated for 3 h with a mixture containing 1.0 µg of pAP-1-luc, 250 ng pSV-β-gal, and 2 µl of Fugene 6 (Roche Molecular Biochemicals, Indianapolis, IN) in 2.5 ml OPTI-MEM media (GIBCO). The transfection mixture was then replaced with fresh complete medium for 24 h. Transfected cells were treated with arsenicals for 8 h, after which cells were washed twice with ice-cold PBS and lysed in 100 µl of lysis buffer (Tropix, Applied Biosystems, Bedford, MA) with 0.5 mM DTT. Cell lysates were clarified by centrifugation at 14,000g for 2 min (4°C) and stored at −80°C. Luciferase and β-galactosidase activities were determined in 10-µl aliquots of cell lysates by using a Dual-Light Kit (Tropix). The luminescence signals associated with the two enzyme activities were quantified by a TR717 microplate luminometer (Tropix). The AP-1-dependent promoter activity was expressed as a normalized luciferase activity (luciferase units/β-galactosidase units).
Statistical analysis
All experiments were replicated to ensure the reproducibility of results. Representative findings are shown. Results of the cell viability, proliferation, and promoter-reporter assays were evaluated by using a GraphPad Instat statistical software package (GraphPad Software, San Diego, CA). Variations among means in a treatment group were analyzed by ANOVA. Each treatment group included cells treated with various concentrations of an arsenical and control (untreated) cells. The Dunnett multiple comparison test was used to evaluate differences between treated and control cells in treatment groups with statistically significant (P<0.05) variation among means.
RESULTS
Metabolism and toxicity of arsenicals in UROtsa cells
Before examination of DNA binding activity and composition of AP-1 in UROtsa cells, the metabolic fate and toxicity of arsenicals in these cells were determined. In metabolic experiments, UROtsa cells exposed to 0.1 µM [
73 As]iAs III for up to 48 h produced no radiolabeled methylated metabolite, indicating that this cell line does not methylate iAs (data not shown). Cell viability and proliferation were examined in cell monolayers exposed to inorganic and methylated trivalent arsenicals (0.1-5 µM) or to inorganic and methylated pentavalent arsenicals (1-200 µM) for 2 or 24 h. Exposures to iAs III or DMAs III and to low concentrations of MAs III O did not affect cell viability as measured by the MTT assay (Fig. 1a, b) . The rate of MTT reduction was significantly decreased only in cells exposed to 5 µM MAs (Fig. 3a) . Incubation of the DNA-protein binding mixture in the presence of antibodies against p-c-Jun shifted almost entire AP-1-DNA complex, indicating that p-c-Jun is a major constituent of the activated AP-1 dimer. The p-c-Jun-related supershifts were found in UROtsa cells treated with trivalent arsenicals and also in untreated (control) cells, which indicated that p-c-Jun is present in AP-1 regardless of the treatment. Incubation of the assay mixtures in the presence of antibodies against c-Jun resulted in supershifts similar to those produced by antibodies against p-c-Jun. In contrast, antibodies against c-Fos had little or no effect on electrophoretic mobility of the AP-1 complex in all treatment groups, which suggested that under these conditions c-Fos is not a significant constituent. A nuclear protein extract from 3T3 SR cells served as a positive control for this analysis. Incubation of this extract in the DNA-protein binding mixture that contained antibodies against c-Fos resulted in a distinct supershift, which indicated the presence of c-Fos in the AP-1 complex. Addition of a neutralizing peptide into the mixture completely prevented the occurrence of the supershift, which confirmed the specificity of the c-Fos antibodies. The specificity of the DNA binding assay for AP-1 was confirmed with a 50-fold excess of unlabeled wild-type or mutant AP-1 probe. To ensure accuracy of the EMSA supershift data and to examine participation of other AP-1 constituents in the AP-1-DNA binding complex, additional analyses were carried out with antibodies supplied from two independent sources, including antibodies against c-Jun, JunB, JunD, c-Fos, and FosB (Geneka Biotechnology), and antibodies against Fra-1, ATF-2, and p-ATF-2 (Santa Cruz Biotechnology). Here, the most notable supershifts were observed in nuclear extracts incubated in the presence of antibodies against cJun, JunD, and especially Fra-1 (Fig. 3b) . Because the c-Jun antibody supplied by Santa Cruz Biotechnology is known to cross-react with JunB and JunD, the supershift data obtained with the antibody from Geneka Biotechnology are likely to provide a more accurate estimate of the presence of c-Jun in the AP-1-DNA binding complex. The Geneka antibody is (according to the manufacturer's information) strictly specific for c-Jun and does not cross-react with other proteins of the Jun family. Notably, antibodies against JunB caused a distinct supershift when incubated with nuclear extracts from cells treated with MAs III O. A similar, but less pronounced, JunB-related supershift was detected in other treatment groups. No supershifts were detected in extracts incubated with antibodies against c-Fos and FosB or against ATF-2 and p-ATF-2.
Expression and activation of AP-1 constituents in cells exposed to arsenicals
The concentrations of AP-1 constituents were determined by immunoblot analysis in nuclear protein extracts from cells treated with trivalent arsenicals and from control cells. This analysis focused on p-c-Jun and Fra-1, proteins identified by the EMSA supershift assay as the major components of the AP-1-DNA binding complex. All trivalent arsenicals modified nuclear levels of p-c-Jun (Fig. 4) . Treatments with low concentrations of iAs III (0.1 and 0.5 µM) decreased nuclear p-c-Jun levels. However, exposure to 1 or 5 µM iAs III increased p-c-Jun levels in a concentration-dependent manner. Both methylated trivalent arsenicals, MAs (Fig. 5) . Nuclear c-Fos levels were at or below the detection limit of the method in either treated or untreated cells. To ensure the accuracy of c-Fos analysis by the immunoblot, nuclear extracts from 3T3 SR cells expressing c-Fos and nuclear extracts from HeLa cells treated with TPA (25 ng/ml, 2 h) were used as positive controls.
To localize c-Fos, additional analyses were performed in cytoplasmic protein extracts from exposed and control cells. Unlike nuclear c-Fos, cytoplasmic c-Fos was detected by immunoblot assay under all treatment conditions. The cytoplasmic c-Fos levels were slightly increased in cells exposed to trivalent arsenicals, particularly in cells exposed to MAs 
Induction of AP-1-dependent gene expression by trivalent arsenicals
To examine the effects of trivalent arsenicals on AP-1-dependent gene transcription in intact cells, UROtsa cells were transiently cotransfected with pAP-1-luc, an AP-1-dependent promoterreporter construct containing cDNA for firefly luciferase, and the constitutively active construct pSV-β-gal. Notably, the transfection efficiency did not exceed 1% under the given transfection conditions. The luciferase and β-galactosidase activities were measured in cells treated with arsenicals (1 or 5 µM) for 8 h and in untreated cells. The activity of constitutively expressed β-galactosidase was used to normalize well-to-well variations in transfection efficiency, cell number, and viability. In transfected UROtsa cells, treatment with only iAs III 
Effects of trivalent arsenicals on enzymes of the MAPK family
To identify upstream mechanisms responsible for c-Jun phosphorylation and AP-1 activation by trivalent arsenicals, protein extracts from control and exposed cells were analyzed for the presence of the parent and activated (phosphorylated) forms of enzymes of the MAPK family, JNK, p38, and ERK. No changes were detected in the concentrations of JNK1, JNK2, and p38, nor was induction of the corresponding phosphorylated forms (p-JNK1, p-JNK2, and p-p38) seen, in cells treated with iAs III or DMAs III I (0.1 to 5 µM) for up to 2 h (data not shown). Similarly, exposures to MAs III O, the most potent inducer of c-Jun phosphorylation, did not alter the immunoblot patterns for either JNK or p38 kinases (Fig. 8) (Fig. 9c) .
DISCUSSION
The role of AP-1 activation in arsenic carcinogenesis was previously examined in both in vitro and in vivo models. Most work has focused on effects induced in laboratory animals or cultured cells by exposure to iAs III , the species commonly regarded as the most toxic and carcinogenic among biologically relevant arsenicals. In normal human epidermal keratinocytes, 4 µM iAs III has been shown to stimulate c-jun and c-fos transcription and activate AP-1 DNA binding (11) . Notably, treatments with submicromolar or micromolar concentrations of iAs III induced production of growth-promoting cytokines and cell proliferation in these cells (11, 41) . Similar effects of iAs III on cell proliferation and c-jun and c-fos transcription were found in a human bladder epithelial cell line, UROtsa (13) . In these cells, short-time exposures to 5 µM iAs III resulted in only a marginal increase in c-fos, but not in c-jun, mRNA levels. Greater increases in both c-fos and c-jun mRNA levels were found only after exposures to 50 µM iAs III . In addition, AP-1 DNA binding activity was increased in cells exposed to 50 µM but not to 5 µM iAs III (13) . In agreement with in vitro studies, increased AP-1 DNA binding activity was also reported in urinary bladder epithelium of mice chronically exposed to high concentrations of iAs III (5-100 mg/L) in drinking water (42) . Activating effects of iAs III on c-Jun and c-Fos expression or AP-1 DNA binding have been confirmed in HeLa cells (12) , human embryonic kidney (HEK 293) cells (43) , human breast cancer (MDA-MB-435) and rat hepatoma (H4IIE) cells (10) , and mouse epidermal (Cl 41) cells (16) , and in precision-cut rat lung slices (44) . The concentrations of iAs . However, because these investigators did not specify the chemical composition of MAs and DMAs used in their study, it is unclear whether these effects depended on the oxidation state of arsenic in the test compounds.
Recent information on adverse biological effects of methylated trivalent arsenicals as potent enzyme inhibitors and cytotoxins (23) (24) (25) (26) (27) (28) indicate that these metabolites of iAs play significant roles in the overall toxicity and carcinogenicity of this metalloid. The current study compared the effects of inorganic and methylated trivalent or pentavalent arsenicals on AP-1 DNA binding activity and on expression of AP-1 constituents in UROtsa cells. UROtsa, an SV40-immortalized cell line, was derived from normal human urothelium lining the ureter (37, 38) . This cell line does not display the characteristics of neoplastic transformation, as exemplified by lack of colony formation in soft agar and growth of tumors in nude mice. UROtsa cells do not express arsenic methyltransferase (45) and do not methylate arsenicals (23, 25) . Thus, iAs and MAs species added into the UROtsa do not undergo oxidative methylation. All trivalent arsenicals examined in this study, iAs The immunoblot analyses of the major AP-1 constituents showed significant increases in p-c-Jun levels in nuclear extracts from UROtsa cells exposed to trivalent arsenicals. Similar to its effects on AP-1 DNA binding patterns, MAs III O was also the most potent inducer of p-c-Jun in this cell line. In contrast, nuclear c-Jun levels were unchanged, which suggests that a post-transcriptional modification, phosphorylation, rather than de novo synthesis, was responsible for the increased nuclear p-c-Jun levels in exposed cells. Thus, the phosphorylation of c-Jun that is induced by trivalent arsenicals at concentrations as low as 0.5-1 µM may be a more sensitive marker of the exposure than is the induction of c-Jun expression. Compared with nuclear p-c-Jun, a smaller increase in nuclear Fra-1 was detected in cells exposed to trivalent arsenicals, particularly to MAs III O. A distinct electrophoretic shift from low to high molecular mass protein bands occurred in Fra-1 protein fractions in exposed cells (Fig. 6) . A similar shift in fibroblasts exposed to TPA was previously described by Gruda and associates (48) , who showed that this shift is associated with an increased presence of the phosphorylated form of Fra-1 (p-Fra-1) in exposed cells. Thus, In general, c-Jun-containing AP-1 dimers have been associated with the induction of cell proliferation (46, 47, 49, 50) . Here, we found that exposures to nontoxic concentrations of trivalent arsenicals did not increase the 24-h cell proliferation rates in UROtsa cells. Because UROtsa is a very rapidly proliferating cell line, the pro-proliferative effects of arsenicals may be too small to be detected on the background of the constitutively high proliferation rate over a relatively short 24-h interval. In comparison, low concentrations of iAs Several studies have shown that activation of JNK and/or p38 is required for AP-1 activation in cultured cells exposed to 40-300 µM iAs III (12, 16, 43) . In our study, increased levels of p-ERK1 and/or p-ERK2, but not p-JNK1 and p-JNK2 or p-p38, were detected in UROtsa cells exposed to much lower concentrations of trivalent arsenicals. The kinetic pattern of ERK1 and ERK2 phosphorylation in cells exposed to arsenicals resembles that of p-c-Jun formation, which suggests that ERK1 and/or ERK2 is directly involved in c-Jun phosphorylation. Although JNKs are regarded as the most specific and efficient enzymes involved in phosphorylation of c-Jun (47), other protein kinases, including Abl tyrosine protein kinase (51) and ERK (52, 53) , phosphorylate this transcription factor. For example, ERK was involved in c-Jun phosphorylation and AP-1 activation in p53-deficient human lung cancer cells exposed to hydrogen peroxide (54) . Notably, exposures to inorganic and methylated arsenicals are known to induce oxidative stress in cultured cells (55, 56) . It is possible that the activation of ERK/p-c-Jun pathway in UROtsa cells exposed to iAs I is mediated by an increased production of reactive oxygen species. Activation of ERK1,2 by trivalent arsenicals may also be responsible for increased phosphorylation of Fra-1 that was detected in exposed cells as a shift in the electrophoretic mobility of the Fra-1 protein fractions during the immunoblot analysis. The transactivation of Fra-1 by ERK has been reported by Young and associates in JB6 cells (57) . In these cells, the ERK-dependent transactivation of Fra-1 was a prerequisite for a mitogen-induced activation of AP-1. Activation of ERK1 and/or ERK2 by iAs III was previously described in several types of animal and human cells (58, 59) . Notably, activation of ERK1,2, but not JNK, was required for iAs III -induced cell transformation (59) . In our study, we showed that methylated trivalent arsenicals were at least equipotent with iAs III as inducers of ERK phosphorylation in human urothelial cells. Simeonova and associates (60) reported that activation of the epidermal growth factor receptor provides the initial signal for ERK phosphorylation in UROtsa cells exposed to iAs III . The upstream mechanisms as well as quantitative and qualitative aspects of the ERK activation by methylated trivalent arsenicals remain to be examined. Preliminary studies carried out in this laboratory showed that inhibition of MAPK/ERK kinase (MEK) in UROtsa cells exposed to trivalent arsenicals completely blocks phosphorylation of ERK 1 and ERK2 but only partially suppresses p-c-Jun levels (Drobna et al., unpublished data). These data indicate that although ERK 1 and ERK2 are at least in part responsible for c-Jun phosphorylation, other protein kinases may be involved in this process.
In conclusion, exposures to trivalent arsenicals, iAs ) are considerably more potent AP-1 activators than is the parent compound in cells derived from urinary bladder, one of the target tissues for carcinogenesis in humans chronically exposed to iAs. These findings support the hypothesis that the biomethylation is a process that activates iAs as a toxin and human carcinogen. Further studies of the downstream events associated with the AP-1 activation induced by arsenic metabolites in human urinary bladder will elucidate the mechanisms by which arsenicals produce their toxic and carcinogenic effects. 
